FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide

Article summary

EMA rejects Omeros' Yartemlea for TA-TMA, citing insufficient efficacy data, despite FDA approval and U.S. launch.